image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 150.36
4.13 %
$ 8.12 B
Market Cap
-26.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MASI stock under the worst case scenario is HIDDEN Compared to the current market price of 150 USD, Masimo Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MASI stock under the base case scenario is HIDDEN Compared to the current market price of 150 USD, Masimo Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MASI stock under the best case scenario is HIDDEN Compared to the current market price of 150 USD, Masimo Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MASI

image
$200.0$200.0$190.0$190.0$180.0$180.0$170.0$170.0$160.0$160.0$150.0$150.0$140.0$140.0$130.0$130.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
2.09 B REVENUE
2.26%
-267 M OPERATING INCOME
-195.38%
-305 M NET INCOME
-374.11%
196 M OPERATING CASH FLOW
108.71%
-51.2 M INVESTING CASH FLOW
36.95%
-126 M FINANCING CASH FLOW
-119.96%
601 M REVENUE
19.04%
-359 M OPERATING INCOME
-1193.02%
-350 M NET INCOME
-3567.35%
50.5 M OPERATING CASH FLOW
97.27%
-16.5 M INVESTING CASH FLOW
-22.22%
-6.5 M FINANCING CASH FLOW
-306.25%
Balance Sheet Masimo Corporation
image
Current Assets 1.23 B
Cash & Short-Term Investments 178 M
Receivables 531 M
Other Current Assets 517 M
Non-Current Assets 1.4 B
Long-Term Investments 8.6 M
PP&E 382 M
Other Non-Current Assets 1.01 B
6.76 %20.22 %19.70 %14.53 %38.45 %Total Assets$2.6b
Current Liabilities 618 M
Accounts Payable 253 M
Short-Term Debt 0
Other Current Liabilities 365 M
Non-Current Liabilities 956 M
Long-Term Debt 728 M
Other Non-Current Liabilities 228 M
16.06 %23.19 %46.25 %14.50 %Total Liabilities$1.6b
EFFICIENCY
Earnings Waterfall Masimo Corporation
image
Revenue 2.09 B
Cost Of Revenue 1.09 B
Gross Profit 1 B
Operating Expenses 1.27 B
Operating Income -267 M
Other Expenses 38.2 M
Net Income -305 M
3b3b2b2b2b2b1b1b500m500m00(500m)(500m)2b(1b)1b(1b)(267m)(38m)(305m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
47.96% GROSS MARGIN
47.96%
-12.73% OPERATING MARGIN
-12.73%
-14.56% NET MARGIN
-14.56%
-28.99% ROE
-28.99%
-11.61% ROA
-11.61%
-13.26% ROIC
-13.26%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Masimo Corporation
image
400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -305 M
Depreciation & Amortization 103 M
Capital Expenditures -20 M
Stock-Based Compensation 41.5 M
Change in Working Capital 0
Others 395 M
Free Cash Flow 176 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Masimo Corporation
image
Wall Street analysts predict an average 1-year price target for MASI of $175 , with forecasts ranging from a low of $160 to a high of $210 .
MASI Lowest Price Target Wall Street Target
160 USD 6.41%
MASI Average Price Target Wall Street Target
175 USD 16.39%
MASI Highest Price Target Wall Street Target
210 USD 39.66%
Price
Max Price Target
Min Price Target
Average Price Target
220220200200180180160160140140120120100100May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Masimo Corporation
image
Sold
0-3 MONTHS
5.37 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
5.45 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
3 Stocks to Buy for "Liberation" From Trump Tariffs & Recession Woes In 2025, companies like MASI, BSX and HIMS are expected to overcome challenges and sustain strong growth and market leadership. zacks.com - 2 weeks ago
Masimo (MASI) is an Incredible Growth Stock: 3 Reasons Why Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com - 2 weeks ago
Masimo to Present in the 24th Annual Needham Virtual Healthcare Conference IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 2:15 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide ar. businesswire.com - 2 weeks ago
Why Masimo (MASI) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 1 month ago
3 Reasons Growth Investors Will Love Masimo (MASI) Masimo (MASI) could produce exceptional returns because of its solid growth attributes. zacks.com - 1 month ago
Buy 3 Momentum Anomaly Stocks as Tariffs Take a Toll on Markets MASI, HOOD and DFS are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it. zacks.com - 1 month ago
Masimo Corporation (MASI) Hit a 52 Week High, Can the Run Continue? Masimo (MASI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 1 month ago
Earnings Estimates Moving Higher for Masimo (MASI): Time to Buy? Masimo (MASI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. zacks.com - 1 month ago
Here's Why Masimo (MASI) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 month ago
Here is Why Growth Investors Should Buy Masimo (MASI) Now Masimo (MASI) possesses solid growth attributes, which could help it handily outperform the market. zacks.com - 1 month ago
Masimo to Present in the 46th Annual Raymond James Institutional Investor Conference IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the 46th Annual Raymond James Institutional Investor Conference on Tuesday, March 4, 2025 at 11:35 a.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces. businesswire.com - 1 month ago
Masimo (MASI) Upgraded to Strong Buy: What Does It Mean for the Stock? Masimo (MASI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 month ago
8. Profile Summary

Masimo Corporation MASI

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 8.12 B
Dividend Yield 0.00%
Description Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
Contact 52 Discovery, Irvine, CA, 92618 https://www.masimo.com
IPO Date Aug. 8, 2007
Employees 3600
Officers Mr. Paul Hataishi Senior Vice President & Chief Accounting Officer Mr. Bilal Muhsin Chief Operating Officer Dr. Steven J. Barker Chairman of Scientific Advisory Board & Chief Science Officer Mr. Blair Tripodi Chief Operating Officer of Consumer Division Ms. Catherine M. Szyman Chief Executive Officer & Director Mr. Yongsam Lee Executive Vice President & Chief Information Officer Mr. Eli Kammerman Vice President of Business Development & Investor Relations Tetsuro Maniwa President of Masimo Japan Mr. Anand Sampath Executive Vice President of Operations & Clinical Research